Imunon, Inc. (IMNN)
About Imunon, Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $500.0K
- Net income
- -$14.5M
- Total assets
- $12.3M
- Market cap
- $8.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $14.7M
- Operating income
- -$14.7M
- Net income
- -$14.5M
- EPS (basic)
- $-6.83
- EPS (diluted)
- $-6.83
Balance sheet
- Total assets
- $12.3M
- Current assets
- $10.7M
- Total liabilities
- $5.2M
- Current liabilities
- $4.6M
- Shareholders’ equity
- $7.1M
Cash flow
- Operating cash flow
- -$13.9M
- Investing cash flow
- -$280.6K
- Financing cash flow
- $17.1M
- Net cash flow
- $2.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $8.7M
- EPS (diluted)
- $-6.83
- Shares outstanding
- 5.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 1995
Imunon, Inc. (IMNN) Stock Price
- Reported a net loss of $14.5M in FY2022.
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Imunon, Inc..
Write a review
News about Imunon, Inc.
News & sentiment via Polygon.io
Imunon, Inc.: frequently asked questions
Is Imunon, Inc. an American company?
Imunon, Inc. is a US-based company headquartered in Lawrenceville, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Imunon, Inc. headquartered?
Imunon, Inc. is headquartered in Lawrenceville, New Jersey, United States.
Is Imunon, Inc. publicly traded?
Yes — Imunon, Inc. is a publicly traded company. Its stock trades under the ticker symbol IMNN on the NASDAQ.
What does Imunon, Inc. do?
Imunon, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
